Intel Drops 29% at the Open as Pharma Stocks Lead Gainers

As seen on the 24/7 Wall St. homepage on October 30, 2026.

Biggest movers · On the open 9:50am ET

Gainers

REGNRegeneron$914.2+11.7%
AZNAstraZeneca$186.72+7.1%
TAKTakeda Pharmaceutical$21.21+6.0%
GILDGilead Sciences$174.95+5.6%
MDLZMondelez International$65.63+5.0%

Losers

INTCIntel$65.27-29.1%
APPSDigital Turbine$9.26-12.4%
MSTRStrategy$125.22-11.6%
DOCNDigitalOcean$89.25-10.7%
DDOGDatadog$238.8-10.2%

Intel opened down 29%, a one-day drop of a size this name almost never posts, while the top of the board belongs entirely to pharma, led by Regeneron. Four of the five biggest decliners fell by double digits.

Continue ReadingShow less

Intel's 29.11% opening loss is the kind of single-session move that defines a stock for years, placing it at the bottom of the broader market by a wide margin.

Technology and crypto-adjacent names dominate the losers board, with Digital Turbine, Strategy, DigitalOcean and Datadog all down double digits. Four of the five biggest decliners point to broad pressure across growth-oriented technology.

Sources

Mentioned: INTC, REGN, AZN, TAK, GILD, MDLZ, MSTR, DDOG

Related Market Updates

DDOG Datadog

Regular session

12:20pm ET

$231.01

-9.00% open $253.87

A 9% intraday slide to $231.01 takes roughly $7 billion off Datadog's $77.7 billion market value in a single session. Moves this size are rare for the observability leader, and where it settles into the close sets the next reference point.

SNY Sanofi

Q3 2026

8:49am ET

EPS

$3.97

est $1.51 +162.8%

Revenue

$16.15B

est $13.28B +21.7%

Dupixent sales jumped 34.8% to $6.36 billion, beating expectations and lifting full-year guidance. Management is already spending the windfall, expanding the Regeneron alliance to protect earnings through Dupixent's eventual loss of exclusivity.

AZN AstraZeneca

Q3 2026

7:36am ET

EPS

$2.79

est $1.15 +143.5%

Revenue

$16.21B

est $16.00B +1.3%

Oncology revenue rose 17%, more than absorbing a 25% drop in Farxiga after US generics arrived, and AstraZeneca still beat EPS expectations. Management reaffirmed full-year guidance and pointed to 2027 readouts.

Earnings · 2026 Q3 Pascal Soriot CEO

7:36am ET

We have had approvals for four new medicines and reported 12 positive Phase III programme readouts with a collective peak year revenue potential well in excess of ten billion dollars. Our rich series of upcoming readouts in 2027 has a potential of more than twenty billion dollars.

Soriot is putting a dollar figure on AstraZeneca's 2027 catalyst calendar, and it is double what this year's dozen Phase III wins carry. For a $270 billion drugmaker, the pipeline math is now the whole investment case.

REGN Regeneron

Q3 2026

6:50am ET

EPS

$20.07

est $16.19 +23.9%

Revenue

$5.12B

est $4.56B +12.1%

Collaboration revenue jumped 68% to $2.72 billion on record Dupixent sales, with both lines beating expectations. Full-year non-GAAP gross margin guidance moved to roughly 86%.

INTC Intel

Q3 2026

Oct 29, 4:08pm ET

EPS

$0.52

est $0.40 +31.6%

Revenue

$16.51B

est $16.47B +0.2%

Data Center and AI revenue jumped 78% to $7.32 billion, carrying the quarter past expectations. The catch is Q4 guidance of $15.0 billion to $16.0 billion, a sequential step down, with management warning the PC slowdown runs at least through the first half of 2027.

GILD Gilead Sciences

Q3 2026

Oct 29, 4:03pm ET

EPS

$2.55

est $2.21 +15.6%

Revenue

$8.30B

est $7.81B +6.3%

Management has now raised full-year product sales guidance three times this year, a cumulative $1.6 billion increase since January, on 18% HIV sales growth. New twice-yearly PrEP drug Yeztugo is the engine behind it.

Earnings · 2026 Q3 Daniel O'Day CEO

Oct 29, 4:03pm ET

Our performance enabled us to raise our full year base business revenue guidance again this quarter, bringing the total increase to $1.6 billion since the start of 2026. Our HIV business grew 18% and HIV prevention sales nearly doubled year-over-year.

Third guidance raise of the year for Gilead, and the prevention franchise is now doing the heavy lifting as Yeztugo scales. CEO Daniel O'Day framed the Q3 report around a base business that keeps outrunning the company's own forecasts.

MSTR Strategy

Q3 2026

Oct 29, 4:03pm ET

EPS

$44.75

est $17.98 +148.9%

Revenue

$125M

est $129M -3.0%

The entire earnings beat came from a $20.91 billion gain on bitcoin holdings, while software revenue slipped year over year and missed expectations. The real change for income investors: all four preferred series move to daily dividend accrual, starting November 1.

INTC Intel

Regular session

Oct 29, 3:15pm ET

$91.30

-4.43% open $95.53

A 4.43% drop to $91.30 takes roughly $21 billion off Intel's $481.9 billion market cap in a single session. Keep an eye on whether the $91 handle holds into the close.

PODCAST Mad Money w/ Jim Cramer Jim Cramer · 44 min

Oct 27, 7:15pm ET

Mad Money w/ Jim Cramer 10/27/26

Cramer rejects the AI all-clear despite Broadcom arranging $63 billion in financing for Anthropic compute
Meta's $25 billion equity raise was five times oversubscribed, but the $60 billion at-the-market program worries him
CoreWeave bonds reaching a 15% yield flagged as the sector's unresolved weak spot
Caller questions on Micron volatility and Revolution Medicines' pancreatic cancer drug

The bull case for data centers today rested on financing rather than profits, and Cramer wants to hear a customer say the chips are minting money before calling it clear. He expects Meta's at-the-market selling to weigh on the stock as supply hits at the wrong moments, with borrowing costs into a Fed decision the swing factor for everything levered to the buildout.